Key statistics
On Friday, Rallybio Corp (RLYB:NSQ) closed at 1.02, 7.37% above its 52-week low of 0.95, set on Nov 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.00 |
---|---|
High | 1.15 |
Low | 0.9886 |
Bid | 1.02 |
Offer | 1.08 |
Previous close | 0.9886 |
Average volume | 60.60k |
---|---|
Shares outstanding | 41.49m |
Free float | 36.75m |
P/E (TTM) | -- |
Market cap | 41.01m USD |
EPS (TTM) | -1.59 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
- Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
- Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
- Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
- Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
- Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
- Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
- Rallybio to Present at Upcoming Investor Conferences
More ▼